Abbott announced new clinical data supporting its minimally invasive therapies for treating Atrial Fibrillation (AFib), specifically its Volt pulsed field ablation (PFA) system and TactiFlex Duo Ablation Catheter. The Volt system demonstrated an 84.2% success rate in treating paroxysmal AFib and a strong safety profile with zero complications. The TactiFlex Duo showed 81% freedom from documented rhythm recurrence in persistent AFib patients and has FDA breakthrough device designation for ventricular tachycardia.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Abbott studies support pulsed field ablation, dual ablation catheters
Abbott announced new clinical data supporting its minimally invasive therapies for treating Atrial Fibrillation (AFib), specifically its Volt pulsed field ablation (PFA) system and TactiFlex Duo Ablation Catheter. The Volt system demonstrated an 84.2% success rate in treating paroxysmal AFib and a strong safety profile with zero complications. The TactiFlex Duo showed 81% freedom from documented rhythm recurrence in persistent AFib patients and has FDA breakthrough device designation for ventricular tachycardia.